https://médecine.top/index.php?action=history&feed=atom&title=Gammapathies_monoclonales
Gammapathies monoclonales - Historique des versions
2026-09-03T00:54:02Z
Historique des révisions pour cette page sur le wiki
MediaWiki 1.35.2
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=5404&oldid=prev
Julien le 2 juillet 2025 à 06:31
2025-07-02T06:31:57Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 2 juillet 2025 à 06:31</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l14" >Ligne 14 :</td>
<td colspan="2" class="diff-lineno">Ligne 14 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Dosage des chaînes légères libres sériques|| Recherche d'un '''rapport kappa/lambda''' anormal || Si absence de gammapathie monoclonale, rapport kappa/lambda ≈ 1</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Dosage des chaînes légères libres sériques|| Recherche d'un '''rapport kappa/lambda''' anormal || Si absence de gammapathie monoclonale, rapport kappa/lambda ≈ 1</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| Protéine de Bence-Jones dans les urines|| Recherche d'une gammapathie monoclonale à chaîne légère || '''CAVE''' le stix urinaire ne réagit qu'avec l'albumine et pas aux chaînes légères dans les urines</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| Protéine de Bence-Jones dans les urines|| Recherche d'une gammapathie monoclonale à chaîne légère || '''CAVE''' le stix urinaire ne réagit qu'avec l'albumine et pas aux chaînes légères dans les urines<ins class="diffchange diffchange-inline">. Abandonné</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Ponction-biopsie de moelle osseuse|| Recherche d'une plasmocytose médullaire monoclonale || </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Ponction-biopsie de moelle osseuse|| Recherche d'une plasmocytose médullaire monoclonale || </div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4517&oldid=prev
Julien : /* Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017 */
2022-01-26T07:41:05Z
<p><span dir="auto"><span class="autocomment">Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 janvier 2022 à 07:41</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l60" >Ligne 60 :</td>
<td colspan="2" class="diff-lineno">Ligne 60 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Pronostic:</u> dosage de la '''β2-microglobuline'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Pronostic:</u> dosage de la '''β2-microglobuline'''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">** '''Chimiothérapie''' d'induction (?)</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Greffe autologue''' de cellules souches hématopoïétiques: non curative mais amélioration de la survie sans progression et de la survie totale</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Greffe autologue''' de cellules souches hématopoïétiques: non curative mais amélioration de la survie sans progression et de la survie totale</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': acide zolédronique ([https://compendium.ch/product/126773-zometa-conc-perf-4-mg-5ml Zometa]) Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': acide zolédronique ([https://compendium.ch/product/126773-zometa-conc-perf-4-mg-5ml Zometa]) Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">** '''Chimiothérapie de maintenance'''</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">*</ins>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u> light-chain cast nephropathy, glomérulopathie des chaînes légères (amyloïde/non-amyloïde) -> traitement = hydratation, alcaliniser urines, dialyse...</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u> light-chain cast nephropathy, glomérulopathie des chaînes légères (amyloïde/non-amyloïde) -> traitement = hydratation, alcaliniser urines, dialyse...</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4516&oldid=prev
Julien : /* Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017 */
2022-01-26T07:36:08Z
<p><span dir="auto"><span class="autocomment">Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 janvier 2022 à 07:36</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l63" >Ligne 63 :</td>
<td colspan="2" class="diff-lineno">Ligne 63 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': acide zolédronique ([https://compendium.ch/product/126773-zometa-conc-perf-4-mg-5ml Zometa]) Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': acide zolédronique ([https://compendium.ch/product/126773-zometa-conc-perf-4-mg-5ml Zometa]) Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* <u>Complications:</u> light-chain cast nephropathy, glomérulopathie des chaînes légères (amyloïde/non-amyloïde) -> traitement = hydratation, alcaliniser urines, dialyse...</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Plasmocytome isolé ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Plasmocytome isolé ===</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4515&oldid=prev
Julien : /* Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017 */
2022-01-26T07:33:57Z
<p><span dir="auto"><span class="autocomment">Myélome multiple Cours Prof Vollenweider, Service de médecine interne, UNIL-CHUV 2017</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 janvier 2022 à 07:33</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l61" >Ligne 61 :</td>
<td colspan="2" class="diff-lineno">Ligne 61 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Greffe autologue''' de cellules souches hématopoïétiques: non curative mais amélioration de la survie sans progression et de la survie totale</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** '''Greffe autologue''' de cellules souches hématopoïétiques: non curative mais amélioration de la survie sans progression et de la survie totale</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** '''Biphosphonates''': <ins class="diffchange diffchange-inline">acide zolédronique ([https://compendium.ch/product/126773-zometa-conc-perf-4-mg-5ml Zometa]) </ins>Zoledronic acid has also been shown to improve survival in MM requiring therapy</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>Si rechute/maladie réfractaire</u>: Several new drugs have been approved in this setting, including proteasome inhibitors (carfilzomib and ixazomib), the immunomodulatory drug pomalidomide ([https://compendium.ch/fr/product/1268449-imnovid-caps-1-mg Imnovid]), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (daratumumab and elotuzumab).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4354&oldid=prev
Julien : /* Bilan étiologique */
2021-10-26T05:00:05Z
<p><span dir="auto"><span class="autocomment">Bilan étiologique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 05:00</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6" >Ligne 6 :</td>
<td colspan="2" class="diff-lineno">Ligne 6 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<br>insuffisance rénale DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) <del class="diffchange diffchange-inline">||</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| CRAB<ins class="diffchange diffchange-inline">|| </ins>|| hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<br>insuffisance rénale DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4353&oldid=prev
Julien : /* Bilan étiologique */
2021-10-26T04:59:46Z
<p><span dir="auto"><span class="autocomment">Bilan étiologique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 04:59</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6" >Ligne 6 :</td>
<td colspan="2" class="diff-lineno">Ligne 6 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<br>insuffisance rénale</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<br>insuffisance rénale DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) ||</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline"> </del>DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) ||</div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4352&oldid=prev
Julien : /* Bilan étiologique */
2021-10-26T04:59:33Z
<p><span dir="auto"><span class="autocomment">Bilan étiologique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 04:59</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6" >Ligne 6 :</td>
<td colspan="2" class="diff-lineno">Ligne 6 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<del class="diffchange diffchange-inline">,</del><br>insuffisance rénale</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme<br>insuffisance rénale</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) ||</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) ||</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4351&oldid=prev
Julien : /* Bilan étiologique */
2021-10-26T04:59:07Z
<p><span dir="auto"><span class="autocomment">Bilan étiologique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 04:59</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l5" >Ligne 5 :</td>
<td colspan="2" class="diff-lineno">Ligne 5 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! Paramètre || Question || Remarque</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">|-</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">| CRAB||hypercalcémie calcium corrigé > 2,75 mmol/l, ou + 0,25 mmol/l au-dessus de la norme,<br>insuffisance rénale</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> DFG < 40 ml/min/1,73 m<sup>2</sup>, ou – 40% en dessous de la clairance normale,<br>anémie < 100 g/l Hb, ou – 20 g/l en-dessous de la norme),<br>lésion(s) osseuse(s) (Bone lesion) lytique(s) ||</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Fichier:Electrophorèse des protéines sériques.png|75px|sans_cadre|gauche]]Electrophorèse des protéines sériques/urinaires||Recherche d'une protéinémie/protéinurie monoclonale ||</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4350&oldid=prev
Julien : /* Myélome asymptomatique */
2021-10-26T04:56:05Z
<p><span dir="auto"><span class="autocomment">Myélome asymptomatique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 04:56</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l36" >Ligne 36 :</td>
<td colspan="2" class="diff-lineno">Ligne 36 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Synonyme: myélome multiple indolent = ''smoldering multiple myeloma''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Synonyme: myélome multiple indolent = ''smoldering multiple myeloma''</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** Paraprotéine sérique ('''IgG''' ou '''IgA''') <del class="diffchange diffchange-inline">> </del>30 g/L <u>ou</u> immunoglobulinurie <del class="diffchange diffchange-inline">> </del>500 mg/24h <u>et</u></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** Paraprotéine sérique ('''IgG''' ou '''IgA''') <ins class="diffchange diffchange-inline">≥ </ins>30 g/L <u>ou</u> immunoglobulinurie <ins class="diffchange diffchange-inline">≥ </ins>500 mg/24h <u>et</u></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** Plasmocytose médullaire clonale <del class="diffchange diffchange-inline">entre </del>10 et 60%</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** Plasmocytose médullaire clonale <ins class="diffchange diffchange-inline">≥ </ins>10<ins class="diffchange diffchange-inline">% </ins>et <ins class="diffchange diffchange-inline">< </ins>60%</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Pas d’atteinte d’organe/tissus en relation</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Pas d’atteinte d’organe/tissus en relation</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Suivi</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Suivi</u></div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Gammapathies_monoclonales&diff=4349&oldid=prev
Julien : /* Myélome asymptomatique */
2021-10-26T04:54:36Z
<p><span dir="auto"><span class="autocomment">Myélome asymptomatique</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 26 octobre 2021 à 04:54</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l34" >Ligne 34 :</td>
<td colspan="2" class="diff-lineno">Ligne 34 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Myélome asymptomatique ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Myélome asymptomatique ==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Synonyme: myélome multiple indolent = ''smoldering multiple myeloma''</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Paraprotéine sérique ('''IgG''' ou '''IgA''') > 30 g/L <u>ou</u> immunoglobulinurie > 500 mg/24h <u>et</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Paraprotéine sérique ('''IgG''' ou '''IgA''') > 30 g/L <u>ou</u> immunoglobulinurie > 500 mg/24h <u>et</u></div></td></tr>
</table>
Julien